EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis. Issue 4 (27th December 2020)

• Record Type: Journal Article
• Authors: Agache, Ioana; Akdis, Cezmi A.; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez‐Arnau, Ana; Gutermuth, Jan; Guttman‐Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y.; O'Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek
• Other Names: Asero Riccardo investigator.; Puga Marta Ferrer investigator.; Nart IgnasiFigueras investigator.; Gadina Massimo investigator.; Kabashima Kenji investigator.; Sugita Kazunari investigator.
• Is Part Of: Allergy. Volume 76:Issue 4(2021)
• Page Start: 988
• Page End: 1009
• Publication Date: 2020-12-27
• Subjects: atopic dermatitis -- dupilumab -- GRADE -- guideline; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.14690
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.